Fatty Liver

Displaying 1 - 7 of 7CSV
Vujasinovic, M., Ebrahimi, F., Roelstraete, B., Bergman, D., Sun, J., Sadr‐Azodi, O., Löhr, J. ‐Matthias, & Ludvigsson, J. F. (2025). Metabolic Dysfunction‐Associated Steatotic Liver Disease and Pancreatic Disease—A Population‐Based Nationwide Cohort and Sibling‐Controlled Study. United European Gastroenterology Journal. Portico. https://doi.org/10.1002/ueg2.12761
Publication Date
Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2024). The first MASH drug therapy on the horizon: Current perspectives of resmetirom. Liver International, 44(7), 1526–1536. Portico. https://doi.org/10.1111/liv.15930
Publication Date
Steffani, M., Geng, Y., Pajvani, U. B., & Schwabe, R. F. (2024). Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction–associated steatohepatitis. Journal of Clinical Investigation, 134(7). https://doi.org/10.1172/jci179710
Publication Date
Yang, W., Ebrahimi, F., Romeo, S., Holmer, M., Vessby, J., Ekstedt, M., Ludvigsson, J. F., Shang, Y., & Hagström, H. (2024). Risk of major adverse liver outcomes among first‐degree relatives of individuals with MASLD. Liver International, 44(5), 1253–1264. Portico. https://doi.org/10.1111/liv.15874
Publication Date
Simon, T. G., Ebrahimi, F., Roelstraete, B., Hagström, H., Sundström, J., & Ludvigsson, J. F. (2023). Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study. Cardiovascular Diabetology, 22(1). https://doi.org/10.1186/s12933-023-02070-5
Publication Date
Palte, E., Duong, J. K., Remotti, H., Burt, J., Makkar, J., Samstein, B., Verna, E. C., Marratta, D., Emond, J. C., & Fox, A. N. (2023). Vibration Controlled Transient Elastography to Evaluate Steatosis in Candidate Living Donors for Liver Transplantation. Transplantation, 107(9), 1991–1998. https://doi.org/10.1097/tp.0000000000004581
Publication Date